Boston Scientific to Acquire Penumbra in Mixed Cash‑Stock Deal

Why It Matters

The merger reshapes the medical‑device market and changes the exposure of PEN derivatives, affecting hedgers and speculators. Precise option adjustments are essential to avoid settlement failures and potential NSCC liability.

Key Takeaways

• PEN shareholders vote May 6 on Boston Scientific merger
• Cash option: $374 per PEN share; stock option: 3.8721 BSX shares
• PEN options convert to BSX1 with 100‑share contract multiplier
• Settlement delayed until non‑electing consideration is finalized
• Uncovered call writers face timing risk around election deadlines

Pulse Analysis

The proposed merger between Penumbra Inc. and Boston Scientific Corp. marks a strategic consolidation in the medical‑device sector, combining Penumbra’s interventional technologies with Boston Scientific’s broader product portfolio. Shareholders will decide on May 6, 2026, with the transaction structured as a hybrid cash‑and‑stock consideration—$374 per PEN share in cash and 3.8721 Boston Scientific shares per PEN share in stock, both rounded and subject to proration. This blend aims to balance immediate liquidity for investors while preserving upside potential through equity participation.

For market participants holding PEN options or futures, the OCC’s contract adjustment is pivotal. Effective the business day after the merger closes, PEN options will be re‑symbolized as BSX1, with the contract multiplier expanding from 1 to 100 shares, effectively turning a $330 premium into a $33,000 exposure. Settlement will be postponed until the non‑electing shareholders’ cash or stock consideration is finalized, ensuring that deliverables reflect the actual merger outcome. The new deliverable mirrors the non‑electing portion of the merger consideration, creating a unique settlement profile that differs from standard equity options.

The broader implications extend to risk management and trading strategies. Uncovered call writers and short futures holders now face heightened timing risk, as they must align exercise or delivery dates with election deadlines and the final determination of fractional cash payments. Failure to meet these windows could trigger NSCC protect‑provision liabilities, potentially increasing costs or forcing forced liquidations. Traders should reassess position sizing, consider hedging with Boston Scientific securities, and monitor OCC communications for any further adjustments as the merger progresses.

Deal Summary

Boston Scientific Corporation announced it will acquire Penumbra, Inc., with shareholders set to vote on the merger on May 6, 2026. The deal offers a mixed cash‑stock consideration of $374 per Penumbra share or 3.8721 Boston Scientific shares, representing a 73.26% cash and 26.74% stock split. The transaction is pending shareholder approval and is expected to close later in 2026.